Natera achieves Q1 2024 cash flow breakeven, reports 52% YoY revenue growth, and raises guidance to $1.42-$1.45bn.
Natera, a molecular testing services company, reported Q1 2024 cash flow breakeven, 52% YoY revenue increase, and record volumes in oncology, organ health, and women's health. The company increased its revenue guidance for the year to $1.42-$1.45bn with a gross margin of 53-55%. Natera's stock surged to a three-year high after its "robust beat-and-raise" and first-ever quarter of positive cash flow.
May 10, 2024
4 Articles